Supernus Pharmaceuticals Inc (LTS:0LB2)
$ 34.68 0.26 (0.76%) Market Cap: 1.92 Bil Enterprise Value: 1.61 Bil PE Ratio: 390.56 PB Ratio: 1.90 GF Score: 82/100

Q4 2018 Supernus Pharmaceuticals Inc Earnings Call Transcript

Feb 27, 2019 / 02:00PM GMT
Release Date Price: $37.08
Operator

Welcome to Supernus Pharmaceuticals' Fourth Quarter and Full Year 2018 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Vozzo of Westwicke Partners, Investor Relations for Supernus Pharmaceuticals. You may begin.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Joel. Good morning, everyone. And thank you for joining us today for Supernus Pharmaceuticals' Fourth Quarter and Full Year 2018 Financial Results Conference Call. Yesterday, after the close of the market, the company issued a press release announcing these results.

On the call with me today are Supernus' Chief Executive Officer, Jack Khattar; and Chief Financial Officer, Greg Patrick. Today's call is being made available via the Investor Relations section of the company's website at ir.supernus.com. Following remarks by management, we will open the call to questions. We expect the duration of the call to be approximately 45 minutes.

During the course of this call,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot